Laurence Petty, MD
Hospice and Palliative Medicine · Plant City, FLNPI 1265655757
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,882 of the $140,020 with a category attached, or 64.9%. 30 manufacturers reported payments, led by UCB, Inc. at 45.8% of the total. Reporting peaked in 2023 at $51,038 and has fallen 82.8% since, to $8,797 in 2025. Among hospice and palliative medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 699 payments — averaging $200.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$64K
- Otsuka America Pharmaceutical, Inc.$25K
- Lilly USA, LLC$22K
- Urovant Sciences Inc$12K
- Acadia Pharmaceuticals Inc$6K
- Neurocrine Biosciences, Inc.$2K
- plus $10K from 24 others
What the payments were for
- Consulting fees$9,7227%
- Speaking & faculty fees$90,88265%
- Travel & lodging$18,29013%
- Food & beverage$21,03115%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 204 | $64,106 |
| Otsuka America Pharmaceutical, Inc. | 63 | $24,511 |
| Lilly USA, LLC | 62 | $21,907 |
| Urovant Sciences Inc | 42 | $11,899 |
| Acadia Pharmaceuticals Inc | 61 | $5,581 |
| Neurocrine Biosciences, Inc. | 42 | $1,696 |
| Avanir Pharmaceuticals, Inc. | 38 | $1,298 |
| AstraZeneca | 31 | $1,240 |
| Sumitomo Pharma America, Inc. | 8 | $1,237 |
| Smith+Nephew | 24 | $1,091 |
| Teva Pharmaceuticals USA, Inc. | 24 | $1,012 |
| Sunovion Pharmaceuticals Inc. | 9 | $869 |
| Jazz Pharmaceuticals Inc. | 17 | $612 |
| SK Life Science, Inc. | 14 | $487 |
| Greenwich Biosciences, Inc. | 9 | $484 |
| Neurelis, Inc. | 15 | $470 |
| Astellas Pharma US Inc | 10 | $348 |
| Sun Pharmaceutical Industries Inc. | 8 | $275 |
| Argenx US, Inc. | 4 | $250 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $198 |
| Eisai Inc. | 1 | $120 |
| Cipher Pharmaceuticals US LLC | 1 | $91 |
| Alpha Cognition USA, Inc. | 1 | $52 |
| Hill-rom Company, Inc | 1 | $38 |
| Johnson & Johnson | 1 | $35 |
| Lundbeck LLC | 2 | $34 |
| Vivus LLC | 1 | $24 |
| Catalyst Pharmaceuticals, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$140,020 in reported general payments places this provider in the 95th percentile of 177 hospice and palliative medicine providers in Florida.
See all hospice and palliative medicine providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 620 | $207,938 |
| GemtesaVibegron | 480 | $128,115 |
| TrulicityDulaglutide | 92 | $67,402 |
| AptiomEslicarbazepine Acetate | 46 | $52,033 |
| NuedextaDextromethorphan Hbr/Quinidine | 67 | $45,433 |
| XareltoRivaroxaban | 101 | $39,408 |
| Divalproex Sodium | 484 | $39,196 |
| OxycontinOxycodone Hcl | 18 | $33,930 |
| BriviactBrivaracetam | 51 | $31,302 |
| NuplazidPimavanserin Tartrate | 12 | $29,827 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 190 | $28,860 |
| TivicayDolutegravir Sodium | 25 | $28,126 |
| ZerbaxaCeftolozane/Tazobactam | 15 | $27,229 |
| RexultiBrexpiprazole | 39 | $27,114 |
| JardianceEmpagliflozin | 70 | $24,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $1,237 | $128,115480 claims |
| Lilly USA, LLCTrulicity | $21,907 | $67,40292 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $869 | $52,03346 claims |
| UCB, Inc.Briviact, Nayzilam | $64,106 | $51,24778 claims |
| Johnson & JohnsonXarelto, Procrit | $35 | $48,993126 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $1,298 | $45,43367 claims |
| Acadia Pharmaceuticals IncNuplazid | $5,581 | $29,82712 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $24,511 | $27,11439 claims |
| AstraZenecaFarxiga, Symbicort | $1,240 | $26,42782 claims |
| Smith+NephewSantyl | $1,091 | $14,49526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 hospice and palliative medicine providers in Florida.
Other hospice and palliative medicine in Plant City
- Michael KaragiozisTemple Terrace$21K
- Young Doo ChangTampa$10K
- Joshua SmithTampa$7K
- Sharon Nickell-OlmEustis$3K
- Lidia OliveiraLake Mary$2K
- William BerkeNorth Miami Beach$2K
- Anthony DardanoBoca Raton$2K
- Diane PortmanTampa$2K
- Armando Linares PerezPinecrest$1K
- Tanveer MirOrlando$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.